Nasdaq · Common Stock · Surgical & Medical Instruments & Apparatus
19 entities across 17 jurisdictions, 2 in offshore financial centres. Read directly from the company’s own 10-K EX-21 filed 2026-02-26 — see the exhibit.
Which other public companies file entities in the same places:
| Entity | Jurisdiction | Note |
|---|---|---|
| Novocure Austria GmbH | Austria | |
| Novocure Belgium S.r.l. | Belgium | |
| Novocure Canada, Inc. | Canada | |
| Novocure Capital S.à.r.l. | Luxembourg | offshore centre |
| Novocure Denmark ApS | Denmark | |
| NovoCure (Israel) Ltd. | Israel | |
| Novocure France SAS | France | |
| NovoCure GmbH | Germany | |
| Novocure Inc. | Delaware | |
| Novocure Italy S.r.L. | Italy | |
| Novocure K.K. | Japan | |
| Novocure Luxembourg S.à.r.l. | Luxembourg | offshore centre |
| Novocure Netherlands B.V. | Netherlands | |
| Novocure Poland Sp. z o.o. | Poland | |
| Novocure Singapore Pte. Ltd. | Singapore | |
| Novocure Spain S.L. | Spain | |
| Novocure Sweden AB | Sweden | |
| Novocure USA LLC | Delaware | |
| Novocure UK Limited | United Kingdom |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $494.4M | $19.8M | $84.2M | 78.5% | 108,877,648 |
| FY2021 | $535.0M | −$58.4M | $58.6M | 78.5% | 103,433,274 |
| FY2022 | $537.8M | −$92.5M | $9.4M | 78.6% | 104,660,476 |
| FY2023 | $509.3M | −$207.0M | −$100.4M | 74.8% | 106,391,178 |
| FY2024 | $605.2M | −$168.6M | −$69.2M | 77.3% | 107,834,368 |
| FY2025 | $655.4M | −$136.2M | −$75.7M | 74.5% | 111,471,991 |
12 institutions tracked — 9 added, 3 reduced, 1 sold out. Active managers added 705,689 shares while index money cut 1,480,407.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| BlackRock, Inc. | Index | 11,863,861 | −1,549,838 | $189.2M |
| AQR CAPITAL MANAGEMENT LLC | Hedge fund | 1,102,131 | +827,199 | $16.7M |
| JPMORGAN CHASE & CO | Active fund | 967,478 | −703,604 | $15.6M |
| BANK OF AMERICA CORP /DE/ | Active fund | 762,724 | +592,711 | $11.6M |
| Point72 Asset Management, L.P. | Hedge fund | 803,120 | −558,271 | $12.2M |
| CITADEL ADVISORS LLC | Hedge fund | 373,735 | +175,499 | $5.7M |
| MORGAN STANLEY | Active fund | 4,697,120 | +174,731 | $74.9M |
| RENAISSANCE TECHNOLOGIES LLC | Hedge fund | 2,117,711 | +165,800 | $33.8M |
| STATE STREET CORP | Index | 2,927,064 | +60,518 | $46.7M |
| PRICE T ROWE ASSOCIATES INC /MD/ | Active fund | 143,949 | +28,847 | $2.2M |
| GEODE CAPITAL MANAGEMENT, LLC | Index | 2,807,264 | +8,913 | $44.8M |
| FMR LLC | Active fund | 17,375,855 | +2,777 | $277.1M |
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register. These filings span 2026-Q2–2026-Q3 rather than a single quarter, because filers report on their own schedules.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
NovoCure Ltd files under SIC 3841 — all 38 surgical & medical instruments & apparatus companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.